Notice Received Under Section 249D of the Corporations Act
Filed with ASX · · 1 page · English
Earlier from TrivarX
- Executive Leadership Changes
- Clinical Study Shows Improvement to Diagnostic Standard
- Preliminary Final Report
- Departure of Managing Director & Chief Executive Officer
- Medibio Submits FDA De Novo Application
Later from TrivarX
- Medibio Releases Corporate Health Product, ilumen
- Receipt of R&D Tax Incentive Refund
- MEB Signs ilumen Contract with Large Australian Employer
- Medibio Appoints CEO and Managing Director
- Medibio Provides Update on FDA Process
Follow TrivarX into a list and get an email when it puts out news.
Follow TrivarX